Accesswire
05 Oct 2026, 06:40 UTC · 4h ago
Genflow Biosciences PLC Announces Presentation of Interim Results
Impact · against what's priced in
Genflow Biosciences' interim dog study results provide directional evidence for SIRT6c but fail to reach statistical significance, increasing the risk of failure at the primary endpoint. The news is partially offset by the company's intent to monetize the veterinary program via asset sale or out-licensing to fund its human pipeline.
- GENF+0.10
No priced-in read yet
- In context
Interim results for the SIRT6c canine study lacked statistical significance (p=0.088), but the intention to out-license the veterinary program provides a path toward non-dilutive funding for human MASH and ophthalmology trials.
Read from the article alone
